Endothelial nitric oxide synthase (eNOS) is protective against kidney injury, but the molecular mechanisms of this protection are poorly understood 1,2 . Nitric oxide-based cellular signalling is generally mediated by protein S-nitrosylation, the oxidative modification of Cys residues to form S-nitrosothiols (SNOs). S-nitrosylation regulates proteins in all functional classes, and is controlled by enzymatic machinery that includes S-nitrosylases and denitrosylases, which add and remove SNO from proteins, respectively 3,4 . In Saccharomyces cerevisiae, the classic metabolic intermediate co-enzyme A (CoA) serves as an endogenous source of SNOs through its conjugation with nitric oxide to form S-nitrosoCoA (SNO-CoA), and S-nitrosylation of proteins by SNO-CoA is governed by its cognate denitrosylase, SNO-CoA reductase (SCoR) 5 .
mice (P = 0.0221) (Fig. 1j) , whereas iron nitrosyl levels (a measure of NO production) were unchanged. These data suggest that protein S-nitrosylation by SNO-CoA protects against AKI.
Protein S-nitrosylation typically operates within multiprotein macro-complexes, in which SCoR may interact directly with SNO targets 4, 8 . Most targets of SCoR in yeast are metabolic enzymes, and alterations in metabolism after AKI may have a protective role 5, 9, 10 . To identify protein targets of S-nitrosylation that mediate protection by the SNO-CoA-SCoR system, we combined three unbiased proteomic and metabolomic screening approaches. First, we coupled resinassisted capture of SNO-proteins (SNO-RAC) with quantitative mass spectrometry. SNO-protein levels were higher in injured Akr1a1 −/− kidneys than in Akr1a1 +/+ kidneys, and we found that 45 SNOproteins were enriched by 1.4-fold or more (Fig. 2a, b , Supplementary  Table 1) . Second, we isolated the AKR1A1 interactome from mouse kidney extracts by immunoprecipitation, identifying 37 proteins (Supplementary Table 2 ). Notably, seven proteins overlapped with the nitrosoproteome (SNO-ome) identified by SNO-RAC, including the prominent metabolic enzyme pyruvate kinase M2 (PKM2) (Fig. 2c, 
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Supplementary Table 3 ). Third, we performed metabolic profiling following AKI (compared with sham injury) in Akr1a1 −/− and Akr1a1 +/+ mice. Multiple upstream glycolytic intermediates accumulated in injured kidneys of Akr1a1 −/− mice, whereas the downstream intermediates pyruvate and lactate did not accumulate ( Fig. 2d-i) . These data suggest a block at the last step in glycolysis-between phosphoenolpyruvate (PEP) and pyruvate-which is catalysed by PKM2 (Fig. 2j ) (note that declines in pyruvate are likely to be prevented via multiple routes, including degradation of amino acids, conversion of lactate to pyruvate, and oxidative decarboxylation of l-malate 11, 12 ). Thus, PKM2 is identified as a SNO-CoA-regulated SNO-protein, a component of the AKR1A1 interactome, and a site of metabolic regulation by the SNO-CoA-SCoR system. These results point to inhibitory S-nitrosylation of PKM2 in injured kidneys of Akr1a1 −/− mice. To verify the regulation of PKM2 by SCoR, we measured the level and activity of S-nitrosylated PKM2 (SNO-PKM2) after AKI. SNO-PKM2 was higher in Akr1a1 −/− than Akr1a1 +/+ kidneys, and increased SNO-PKM2 was associated with lower PKM2 activity; both increased SNO-PKM2 and decreased PKM2 activity were eNOS-dependent ( Fig. 3a-c) . Increased SNO-PKM2 and decreased PKM2 activity in Akr1a1 −/− mice were also correlated with protection against endotoxininduced AKI (Extended Data Fig. 3j-l) . As further validation, we found that PKM2 interacted with AKR1A1 in HEK-293 cells, as it does in native kidneys, and that recombinant PKM2, but not other PK isoforms (PKM1 or PKLR), was directly inhibited by SNO-CoA (Fig. 3d , Extended Data Fig. 4a, b) . Our data indicate that PKM2 activity after AKI is governed by SCoR-regulated S-nitrosylation.
PKM2 has 10 cysteine residues and individual mutation revealed that four cysteine residues-C152, C358, C423 and C424-accounted for +/+ mice in three independent experiments (Expt 1-3; SNO-RAC); injury induced by I/R. c, Proteins found in both the S-nitrosoproteome in b (left circle) and the AKR1A1 interactome (right circle). d-i, Mean ± s.d. glycolytic intermediates glucose-6-phosphate (G6P), fructose-6-phosphate (F6P), dihydroxyacetone phosphate (DHAP), glyceraldehyde-3-phosphate (G3P), 2-phosphoglycerate (2PG), phosphoenolpyruvate (PEP), pyruvate and lactate (G6P/F6P, 2PG, PEP, pyruvate and lactate: Akr1a1 +/+ , n = 10 mice; Akr1a1 −/− , n = 11 mice; DHAP/ G3P: n = 6 mice per group). All data are normalized to wild-type (WT) sham; X, outliers. j, Glycolytic pathway metabolomics, comparing I/R-injured Akr1a1 +/+ and Akr1a1 −/− mice. Intermediates highlighted in orange were increased, in blue were unchanged and in green were not identified. d-i, One-way ANOVA with Tukey post hoc test; numbers above square brackets show P values. 
Letter reSeArCH measurable S-nitrosylation by eNOS (Fig. 3e, Extended Data Fig. 5a ). PKM2 degradation was promoted by C152 mutation (Extended Data Fig. 5b-e) . S-nitrosylation of PKM2 may therefore explain reduced PKM2 expression in Akr1a1 −/− mice (Fig. 3a , Extended Data Fig. 4c, d ). Oxidation of PKM2 at C358 can inhibit PKM2 activity 13, 14 ; however, C423 and C424 are newly discovered regulatory sites. Notably, C423 and C424 are encoded by the PKM2-specific alternative exon 10 and are localized at the interacting surface of the PKM2 tetramer (Extended Data Fig. 6a, b) . The activity of PKM2(C423/424A) cannot be inhibited by SNO-CoA in vitro or by the NO donor DETA-NO in HEK-293 cells, confirming that cysteines 423 and 424 are the principal targets of NO (Fig. 3f, Extended Data Fig. 7a, b) . Using purified proteins, we found that SNO-CoA inhibited the formation of tetrameric wild-type PKM2 but not tetrameric PKM2(C423/424A) (Fig. 3g) . NO promoted the accumulation of PEP in cells expressing Myc-labelled wild-type PKM2 (Myc-PKM2(WT)) but not in those expressing Myc-PKM2(C423/424A) (Fig. 3h) . Thus, S-nitrosylation of C423 and C424 is primarily responsible for inhibition of PKM2 by SNO-CoA.
We investigated how inhibition of a terminal step in glycolysis could confer protection against AKI. Multiple pentose phosphate pathway (PPP)-related intermediates were increased in Akr1a1 −/− kidneys following AKI (Fig. 4a-d) , and NO promoted higher accumulation of PPP intermediates in Myc-PKM2(WT) cells than in Myc-PKM2(C423/424A) cells (Extended Data Fig. 7d ). PPP is a metabolic pathway for generating NADPH 15 , which can increase glutathione (GSH) and activate anti-oxidant enzymes, lessening kidney injury 16 , and we confirmed that the NADPH/NADP + ratio following AKI was higher in kidneys from Akr1a1 −/− mice than from Akr1a1 (Fig. 4e) . Thus, inhibitory S-nitrosylation of PKM2 increases flux through the PPP.
Reactive oxygen species (ROS) are central mediators of AKI 17, 18 , and enhanced antioxidant defences can ameliorate AKI 19, 20 . Tissue indicators of oxidative stress, oxidized GSH (GSSG)/GSH ratio and lipid peroxidation, were lower in injured kidneys from Akr1a1 −/− mice than from Akr1a1 +/+ or Akr1a1 (Fig. 4f, g ) (without a change in total glutathione; Extended Data Fig. 7c ). ROS levels may reflect mitochondrial dysfunction. However, levels of multiple tricarboxylic acid (TCA) cycle intermediates were similar in AKI-injured Akr1a1 −/− and Akr1a1 +/+ mice, and ADP/ATP ratios were no different in Myc-PKM2(WT) than in Myc-PKM2(C423/424A) cells under NO treatment (Extended Data Fig. 8a-d) . We conclude that inhibition of PKM2 by the SNO-CoA-SCoR system shunts metabolic intermediates through the PPP to alleviate oxidative stress and protect against AKI.
To establish conclusively the importance of PKM2 inhibition in protection against AKI and of metabolic reprogramming (PPP versus glycolytic flux) in renal protection, we generated mice in which PKM2 was knocked out specifically in renal tubular epithelial cells (Pkm2 −/− ; Extended Data Fig. 9a ). Levels of PKM2 were markedly reduced in kidneys of Pkm2 −/− mice; however, levels of PKM1 were increased to compensate (Fig. 4h) . Overall, pyruvate kinase activity in the kidney was reduced by about 40%, which recapitulates precisely PKM activity in the injured kidneys of Akr1a1 −/− mice (Figs. 3c, 4i ). Serum creatinine and BUN were significantly lower in Pkm2 −/− than in wild-type mice following AKI (P = 0.002 for creatinine; P = 0.0024 for BUN) (Fig. 4j, k) , indicating renal protection. Histological tubular injury was attenuated in Pkm2 −/− compared with wild-type mice (Fig. 4l, m) . Knockout of PKM2 improved survival (Extended Data  Fig. 9b ). NADPH/NADP + ratios and PEP levels, but not pyruvate levels, were increased in Pkm2 −/− compared with wild-type mice (Fig. 4n , Extended Data Fig. 9c, d ). The GSSG/GSH ratio and lipid peroxidation were lower in injured kidneys from Pkm2 −/− mice than wild-type mice (Fig. 4o, p) . These results confirm that inhibition of PKM2 shifts metabolic flux from energy-generating (glycolytic) to anti-oxidant (PPP) pathways to protect kidneys against AKI. PEP (relative to control) 
The discovery of a physiological function for the SNO-CoA-SCoR system in mammals and in cellular metabolism in particular opens a new field of interdisciplinary inquiry. Notably, our results show that SNO-CoA has an essential role in metabolic regulation. SNO-CoA serves as an endogenous source of NO groups and thus as a mediator of protein S-nitrosylation, including of key metabolic enzymes (Supplementary Table 1 ). By coordinating metabolic flux through glycolysis versus PPP, the SNO-CoA-SCoR system regulates the balance between energy and reducing equivalents to protect against AKI (Fig. 4q) . NO regulates glycolysis in neurons and glia, but the mechanism of this regulation has remained unclear [21] [22] [23] . Our findings suggest that SCoR-regulated, SNO-CoA-mediated protein S-nitrosylation may subserve metabolic signalling more broadly.
AKR1A1 has physiologically relevant SCoR activity in mammals, including dozens of SNO substrates. AKR1A1 has a role in ascorbic acid synthesis in rodents 7 and activity against γ-hydroxybutyric acid (GHB)-related aldehydes in vitro 24 . However, humans do not synthesize ascorbic acid, and AKR1A1 does not regulate GHB in vivo 25 (Extended Data Fig. 7g) . Therefore, the primary function of AKR1A1 has been a mystery 26 . Our work indicates that the major function of AKR1A in mammals is to regulate NO-based metabolic signalling. Notably, eNOS-derived NO has previously been associated with both metabolic regulation and renal protection 1, 2, 27 , but the molecular mechanisms of these effects were poorly understood. Our findings provide an unanticipated mechanistic basis for eNOS-derived NO protection in the kidney, mediated by SNO-CoA and governed by SCoR (Fig. 4q) .
Pyruvate kinases catalyse the final step in glycolysis (Fig. 2j ). PKM1 is expressed in organs with high energy requirements, including the heart, muscle and brain (Extended Data Fig. 6c ), as a constitutively active tetramer, whereas PKM2 is expressed primarily in fetal (and tumour) cells, and can shift reversibly between a tetramer and a lower-activity dimer to reprogram metabolism for growth or survival 13, 28, 29 . Why PKM2 is expressed in some differentiated tissues and predominantly after AKI 9 (Extended Data Fig. 10a -c) has been unclear. We have shown that PKM2 expression enables protection by metabolic reprogramming, and coupled with reduced SCoR activity after AKI (Extended Data Fig. 2c ), suggests physiological regulation. S-nitrosylation of PKM2 by SNO-CoA forces glucose flux into the PPP to detoxify ROS (Fig. 4q ). PKM2 inhibition also increases synthesis of serine, a precursor for lipids, proteins and nucleotides 30 , and serine levels are elevated in Akr1a1 −/− mice following AKI (Extended Data Fig. 7e, f) . Therefore, an additional advantage of metabolic programming via PKM2 may be in regenerating tissues after injury. In contrast to reversible regulation of PKM2 in AKI, irreversible PKM2 +/+ group; n = 11 mice per Akr1a1 −/− group). Injury induced with I/R. X, outliers. d, PPP; intermediates in orange were increased. e, f, NADPH/NADP + and GSSG/GSH ratios (n = 6 mice per group). g, Lipid peroxidation (n = 6 mice per group). h, Expression of PKM2 and PKM1. Quantification (right) is based on 5 mice per group. i, PK activity in kidneys (n = 5 mice per group). j, k, Serum creatinine and BUN after I/R-induced AKI (n = 7 mice per group). l, Haematoxylin and eosin staining of injured kidneys (arrows as in 
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Sham AKI Letter reSeArCH inactivation is associated with diabetic nephropathy 14 . Thus, inhibition of SCoR and/or PKM2 may be advantageous therapeutically in acute injurious conditions, including AKI.
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Mice. Mouse studies were approved by the Case Western Reserve University Institutional Care and Use Committee (IACUC). Housing and procedures complied with the Guide for the Care and Use of Laboratory Animals and the American Veterinary Medical Association guidelines on euthanasia. Akr1a1 +/− mice were made by Deltagen. In brief, to knock out AKR1A1 (SCoR) in embryonic stem cells, the Akr1a1 +/− allele was first created by insertion of a LacZ-Neo cassette in place of exon 2 of the Akr1a1 gene, disrupting in-frame translation of AKR1A1 (Extended Data Fig. 1g, h ). F1 mice were generated by breeding chimeric male mice with C57BL/6 females. F2 homozygous mutant mice were produced by intercrossing F1 heterozygous males and females. Wild-type littermates produced by crossing Akr1a1 +/− and Akr1a1 +/− mice were used as breeding pairs to generate control mice (Akr1a1 31 .
In KSP-cre mice, the cadherin 16 promoter drives Cre to specifically express in epithelial cells of renal tubules 32 .
Genotyping of Akr1a1
+/+ and Akr1a1 −/− mice was performed according to the PCR protocol from Deltagen using the following primers: common forward: 5′-GCAGAGATTCAACAAGTCTCCCCTC-3′; mutant reverse: 5′-GGGCCAGCTCATTCCTCCCACTCAT-3′; common reverse: 5′-AGCTAAGGCTCCGAGCAGTGCTAAC-3′. Genotyping of Akr1a1 −/− Enos −/− mice and Pkm2 −/− mice was performed according to the PCR protocol from Jackson laboratory using the following primers: Enos −/− mutant forward: 5′-AATTCGCCAATGACAAGACG-3′; Enos −/− wildtype forward: 5′-AGGGGAACAAGCCCAGTAGT-3′; Enos −/− common reverse: 5′-CTTGTCCCC TAGGCACCTCT-3′; Pkm2 f l/f l forward: 5′-CCTTCAGGAAGACAGCCAAG-3′; Pkm2 fl/fl reverse: 5′-AGTGCTGCCT GGAATCCTCT-3′; KSP-cre forward: 5′-GCAGATCTGGCTCTCCAAAG-3′; KSP-cre reverse: 5′-AGGCAAATTT TGGTGTACGG-3′. Acute kidney injury. AKI surgery was carried out as described previously 33 . Mice of similar age (9-11 weeks) and body weight (male: 25-28 g; female: 22-25 g) were used for surgery. The mice were anaesthetized with isoflurane (1-3%) in oxygen and then anaesthesia was maintained by adjusting isoflurane (0.75-2.0%) as needed. The fur in the surgical area was removed with clippers and the skin sterilized with 3 times alternating washes of betadine (or chlorhexidine) and alcohol. The mouse was placed on a thermostatic station during surgery. The skin and muscle were cut open along the back to expose both right and left kidneys. Gentle blunt dissection revealed the kidney and a Q-tip was used to mobilize and exteriorize the kidney. A 6-0 silk suture was used to clamp the pedicle to block the blood flow to the kidney to induce renal ischaemia for 23 min in male mice or 50 min in female mice, then the sutures were released to allow reperfusion. The identical steps were performed on both kidneys. A silk suture was used to close the muscle layer of the incision followed by the closure of the skin wound with vicryl. Immediately after the wound closure, 20 ml/kg sterile saline was given intraperitoneally to each mouse. The animal was then kept on a heating pad until it gained full consciousness before being returned to home cage. Mice subjected to surgery without clamping the pedicle were used as sham controls. Mortality at 24 h after AKI for WT, Akr1a1
Enos
−/− and Enos −/− mice is shown in Extended Data Fig. 2g . Serum creatinine and BUN were determined after 24 h of reperfusion upon removal of the kidney (when larger volumes of blood can be collected). Serum creatinine and BUN were measured at University Hospital's Clinical Laboratories.
For the LPS-induced AKI model, LPS (O111:B4, Sigma) in saline (0.9%) was injected intraperitoneally into each mouse (10 mg/kg). Immediately after the injection of LPS, 20 ml/kg sterile saline was given intraperitoneally to each mouse. Serum creatinine and BUN were determined after 16 h. SNO-RAC. SNO-RAC was carried out as described previously 34 . Mouse kidneys were mechanically homogenized in lysis buffer (1 mg/5 μl lysis buffer) containing 100 mM HEPES/1 mM EDTA/100 μM neocuproine (HEN), 50 mM NaCl, 0.1% (vol/vol) Nonidet P-40 (NP-40), the thiol-blocking agent 0.2% S-methylmethanethiosulfonate (MMTS), 1 mM PMSF and protease inhibitors (Roche). After centrifugation (20,000g, 4 °C, 20 min, × 2), SDS and MMTS were added to the supernatants to 2.5% and 0.2% respectively, and incubated at 50 °C for 20 min. Proteins were precipitated with −20 °C acetone, and re-dissolved in 1 ml HEN/1% SDS. Precipitation of proteins was repeated with −20 °C acetone, and the final pellets were resuspended in HEN/1% SDS and protein concentrations determined using the bicinchoninic acid (BCA) method. Total lysates (2 mg) were incubated with freshly prepared 50 mM ascorbate and 50 μl thiopropyl-sepharose (50% slurry) and rotated end-over-end in the dark for 4 h. The bound SNO proteins were sequentially washed with HEN/1% SDS and 10% HEN/0.1% SDS; SNO proteins were then eluted with 10% HEN/1% SDS/10% β-meracaptoethanol and analysed by SDS-PAGE and immunoblotting. iTRAQ-coupled SNO-RAC. iTRAQ (isobaric tags for relative and absolute quantitation)-coupled SNO-RAC was carried out as described previously 5 . Extracts of the kidneys were prepared, and SNO-RAC (4 mg of protein per sample) was carried out as described above. SDS-PAGE gels were Coomassie-blue stained, and lanes were separated into eight segments top-to-bottom and collected in two 1.5-ml tubes. Then, 500 μl of 50% acetonitrile (ACN)/50% 100 mM ammonium bicarbonate was used to wash gel bands for more than 5 h while vortexing. After removal of washing buffer, 400 μl of 100% acetonitrile was added to gel pieces and vortexed for 10 min. After removal of ACN, gel pieces were dried in a speed vacuum dryer for 10 min. Subsequently, 200 μl of 10 mM dithiothreitol (DTT) was added to dry gel pieces and vortexed for 45 min. After removal of the DTT buffer, 200 μl of 55 mM iodoacetamide (IAA) was added to the gel pieces, followed by incubating for 45 min in the dark. After removal of IAA buffer, 400 μl of 1× iTRAQ dissolution solution and 400 μl ACN were used to wash the gel pieces alternately twice. Gel pieces were dried for 10 min in a speed vacuum dryer. Next, 500 ng trypsin in 150 μl 1× iTRAQ buffer was added to dried gel pieces on ice for 30 min, and then incubated overnight at 37 °C. Supernatant from the digested protein solution was transferred to a 1.5-ml tube using gel-loading tips. Then, 200 μl extraction buffer of 60% ACN/5% formic acid was added to gel pieces, vortexed for 30 min, and sonicated for 15 min. The supernatant containing peptide extracts was transferred to a 1.5-ml tube, and extractions were repeated two more times. The final digested solution was dried completely. iTRAQ labelling was performed according to the instructions of iTRAQ Reagents, 4plex Applications Kit. In brief, 30 μl of iTRAQ dissolution buffer (10×) was added to each sample tube (pH > 7), and then iTraq labelling reagents (114, 115, 116, 117) were added to separate sample tubes: one reagent to one sample tube. Labelling reactions were vortexed for more than 5 h at room temperature to ensure complete labelling efficiency. The four labelled samples were mixed together and dried. Next, 160 μl of 5% ACN containing 0.5% TFA was added to the mixed labelled sample and cleaned using C18 ziptips. In brief, C18 tips were wetted 5 times with 20 μl of 50% ACN each time, equilibrated with 100 μl of 5% ACN containing 0.5% TFA. Samples were then loaded to the tip by drawing and expelling for 50 cycles to ensure complete binding. The tips were then washed with 20 μl of 5% ACN containing 0.5% TFA 10 times. Peptides were eluted from tips with 20 μl of 60% ACN containing 0.1% formic acid three times, and eluates were combined and dried for liquid chromatography with tandem mass spectrometry (LC-MS/MS) analysis. Immunoprecipitation. In brief, 15 μg of AKR1A1 polyclonal antibody (Proteintech) was incubated with 50 μl Protein G Sepharose (GE) (1:1 slurry) at 4 °C overnight. After washing with NETN buffer (150 mM NaCl, 20 mM Tris-HCl (pH 8.0), 0.5 mM EDTA, 0.5% (v/v) NP-40, 1 mM PMSF and protease inhibitors cocktail)) three times, AKR1A1 antibody bound to Protein G Sepharose was ready for immunoprecipitation. Mouse kidneys were mechanically homogenized in EBC lysis buffer (120 mM NaCl, 20 mM Tris-HCl (pH 8.0), 0.5 mM EDTA, 0.5% (v/v) NP-40, 1 mM PMSF and protease inhibitors cocktail (1 mg tissue/5 μl lysis buffer)). After centrifugation (20,000g, 4 °C, 20 min, × 2), 2 ml (20 mg/ml) supernatant was pre-cleared by incubation with 50 μl Protein G Sepharose (1:1 slurry) for 1 h at 4 °C. After being spun down at 1,000g for 1 min, the supernatant was transferred into new tubes and incubated with 50 μl anti-AKR1A1 antibody-Protein G Sepharose (1:1 slurry) for 5 h at 4 °C. Beads were washed with NETN buffer and proteins were eluted with 50 μl 0.1 M glycine (pH 2.5) for 10 min at room temperature with shaking. Following centrifugation at 1,000g for 2 min, the eluate was neutralized by the addition of 5 μl Tris-HCl (1.0 M), pH 8.0. Proteins were identified by LC-MS/MS analysis. Co-immunoprecipitation (co-IP) was carried out in HEK-293 cells overexpressing V5-AKR1A1 and Myc-PKM2, by co-transfection using Lipofectamine 2000. Cells were collected and lysed in EBC lysis buffer. Anti-Myc affinity gel (Sigma) was used for co-IP. LC-MS/MS analysis. Digested peptides were separated using a UPLC (Waters) with a Nano-ACQUITY UPLC BEH300 C18 column. Separated peptides were continuously injected into an Orbitrap Elite hybrid mass spectrometer (Thermo Finnigan) using a nanospray emitter (10 μm, New Objective). A linear gradient using mobile phase A (0.1% formic acid in water) and B (100% acetonitrile) was used at a flow rate of 0.3 μl/min, starting with 1% mobile phase B and increasing to 40% B at 65 min for protein interaction identification, or increasing to 40% B at 130 min for iTRAQ experiments. All mass spectrometry data were acquired in positive ion mode. For protein interaction identification, a full MS scan (m/z 350-1,800) at a resolution of 120,000 was conducted, and twenty MS2 scans (m/z 350-1,800) were selected from the twenty most intense peptide peaks of full MS scans. Collision-induced dissociation (CID) cleavage mode was performed at a normalized collision energy of 35%. For iTRAQ experiments, a full MS scan (m/z 300-1,800) at resolution of 120,000 was conducted, and ten MS2 scans Letter reSeArCH (m/z 100-1,600) were activated from the five most intense peptide peaks of the full MS scans. CID and higher-energy collisional dissociation (HCD) cleavage modes were performed alternately on the same peptides selected from full MS scans. The MS2 resolution of HCD was 15,000. The bioinformatic software MassMatrix was used to search MS data against a database composed of sequences of mouse proteins from Uniprot and their reversed sequences as a decoy database. Modifications including oxidation of methionine and labelling of cysteine (IA modifications) were selected as variable modifications in searching. For iTRAQ labelling searching, the MS tags of N terminus, Lys and/or Tyr were selected as variable modifications to test labelling efficiency and fixed modification for iTRAQ analysis. Trypsin was selected as the in silico enzyme to cleave proteins after Lys and Arg. Precursor ion searching was within 10 p.p.m. mass accuracy and product ions within 0.8 Da for CID cleavage mode and 0.02 Da for HCD cleavage mode. 95% confidence interval was required for protein identification. Cloning, expression, and purification of recombinant PKM2. The mammalian cell expression plasmid pCMV-PKM2 (Human) was obtained from Origene. The mammalian cell expression plasmid pcDNA-AKR1A1 was constructed by PCR cloning of human AKR1A1. pCMV-PKM2 cysteine mutants were generated using a QuikChange II Site-Directed Mutagenesis Kit (Agilent). For purification of recombinant PKM2, cDNA encoding PKM2(WT) or PKM2(C423A/424A) was cloned into pET21b (Novagen) to introduce a C-terminal 6×His tag on the expressed protein. The recombinant PKM2 proteins were purified from BL21-CodonPlus Competent Escherichia coli cells (Agilent). Overnight E. coli cultures were sub-cultured into 1 l of LB medium at 5%. At an OD 600 nm of 0.5, cultures were induced with 100 mM IPTG and grown for a further 4 h at 28 °C. Cultures were centrifuged at 4,000g for 10 min to harvest the cells. Cell pellets from 1 l cultures were lysed in 10 ml of 1×PBS buffer containing 1 mM PMSF and protease-inhibitor cocktail by sonication. After centrifugation at 14,500g for 20 min, the supernatant was collected. The lysate was diluted in 30 ml 1×PBS buffer containing 1 mM PMSF and protease-inhibitor cocktail and incubated with 1 ml of Ni-NTA agarose at 4 °C for 1 h with rotation. The slurry was then poured into empty PD-10 columns (GE Healthcare). The beads were washed with 100 ml of 50 mM NaH 2 PO 4 , 300 mM NaCl buffer containing 20 mM imidazole. Elution was done in 2 ml of 50 mM NaH 2 PO 4 , 300 mM NaCl buffer with 250 mM imidazole. Buffer was exchanged with modified Roeder D ((20 mM HEPES (pH 7.9), 20% (v/v) glycerol, 0.1 M KCl, 0.2 mM EDTA)) through a Microcon centrifugal filter device (Millipore). Cell culture, siRNA and related treatments. HEK-293 cells were obtained from ATCC (Manassas, Virginia) and tested for mycoplasma contamination. HEK-293 transfection was done as described previously 35 . siRNA-mediated protein depletion was performed in HEK-293 cells. Two custom PKM2 siRNAs that target the 3′ UTR of human PKM2 (5′-CCAGAUGGCAAGAGGGUG-3′ and 5′-GAUCAACGCCUCACUGAAA-3′) were obtained from Dharmacon. siRNA oligonucleotides (60 pmol per 10 cm plate) were transfected into HEK-293 cells using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's protocol. After 24 h, 5 μg pCMV-control, pCMV-PKM2-WT or pCMV-PKM2-C423/424A were co-transfected with siRNA oligonucleotides (60 pmol per 10 cm plate) into HEK-293 cells using Lipofectamine 2000. After 24 h, cells were treated with 500 μM DETA-NO for 20 h. Cells were then collected for assay. Pyruvate, GHB, PEP, 6PG, ATP, ADP and serine measurement. The amount of pyruvate was measured using a Pyruvate Assay Kit (Sigma). Kidneys from Akr1a1 +/+ , Akr1a1 −/− , Pkm2 +/+ or Pkm2 −/− mice (sham operation or AKI) were mechanically homogenized in pyruvate assay buffer (1 mg/5 μl buffer). After extracts were clarified by centrifugation (20,000g, 4 °C, 20 min, ×2), supernatant was used for assay. GHB in the serum of Akr1a1 +/+ and Akr1a1 −/− mice was measured using the GHB enzymatic assay kit from Buhlmann. Enos −/− mice were mechanically homogenized in lysis buffer (50 mM phosphate buffer, pH 7.0, 150 mM NaCl, 0.1 mM EDTA, 0.1 mM DTPA, 1 mM PMSF, and protease inhibitor mixture (Roche)). Extracts were clarified by centrifugation (20,000g, 4 °C, 20 min, ×2), and protein concentration was determined by BCA assay. The NADPH-dependent SNO-CoA reductase activity was determined spectrophotometrically as described previously 5 . In brief, the assays were performed in 50 mM phosphate buffer (pH 7.0; containing 0.1 mM EDTA and DTPA) with 0.2 mM SNO-CoA and 0.1 mM NADPH. Reactions were initiated by the addition of lysate and allowed to proceed for 1 min. All assays were performed in triplicate.
Photolysis/chemiluminescence. Kidneys from Akr1a1
+/+ and Akr1a1 −/− mice were mechanically homogenized in lysis buffer (50 mM phosphate buffer, pH 7.0, 150 mM NaCl, 0.1 mM EDTA, 0.1 mM DTPA, 1 mM PMSF, and protease inhibitor mixture (Roche)). Extracts were clarified by centrifugation (20,000g, 4 °C, 20 min, ×2), and protein concentration was determined by BCA assay. Measurements of XNO/SNO (where XNO is predominantly metal-NO (MNO)) in lysates were done using photolysis/chemiluminescence essentially as described 36 . In brief, NO released from MNO/SNO by UV-photolysis was detected by chemiluminescence generated by the reaction of NO with ozone. Pre-treatment of samples with HgCl 2 (1 mM) (Hg 2+ -coupled photolysis/chemiluminescence) removes SNO specifically and allows differentiation between SNO and other photolysable NO species (predominantly MNO). Histological analysis. Kidney samples were fixed with 4% PFA for 24 h, dehydrated and embedded into paraffin blocks. Formalin-fixed, paraffin-embedded blocks were sectioned and stained with haematoxylin and eosin. For immunohistochemistry staining, paraffin sections were dewaxed and rehydrated. Antigen retrieval was performed by boiling sections in 0.01 M sodium citrate buffer (pH 6.0) for 20 min, then sections were washed three times with PBS. Rabbit polyclonal anti-AKR1A1 (15054-1-AP, Proteintech Group, 1:100) or rabbit polyclonal anti-PKM2 (ABS245, EMD Millipore, 1:100) was dropped onto sections and incubated at 4 °C overnight. After washing with PBS, secondary antibody (HRPassociated goat anti-rabbit) was dropped onto sections and incubated at room temperature for 1 h. Diaminobenzidine (DAB) was used for coloration. More than ten microscopic fields obtained from each animal were selected for quantitative analysis. Renal histopathologic alterations were evaluated and graded on a 0 to 2 scale as described previously 37, 38 . Electron microscopy. Mice were perfused transcardially with quarter-strength Karnovsky's fixative solution at a flow rate of 10 ml/min for 10 min. Small pieces of kidney were immersed in triple aldehyde-DMSO 39 . After rinsing in 0.1 M phosphate buffer (pH 7.3), they were post-fixed in ferrocyanide-reduced osmium tetroxide. Another water rinse was followed by an overnight soak in acidified uranyl acetate. After again rinsing in distilled water, the tissue blocks were dehydrated in ascending concentrations of ethanol, passed through propylene oxide, and embedded in Poly/Bed resin. Thin sections were sequentially stained with acidified uranyl acetate followed by a modification of Sato's triple lead stain 40 . These sections were examined in a FEI Tecnai Spirit (T12) transmission electron microscope with a Gatan US4000 4k×4k CCD. PK activity. PKM activity was measured on the basis of generation of pyruvate, which was oxidized by pyruvate oxidase to produce colour (λ = 570 nm). To measure PKM1, PKLR, PKM2(WT) and PKM2(C423/424A) (where both Cys are replaced by Ala) protein activity in vitro, DTT in PKM1 (Sigma) and PKLR (R&D systems) buffer was removed using Amicon Ultra-0.5 ml Centrifugal Filters. In brief, 250 ng recombinant PKM1, PKLR, PKM2(WT) or PKM2(C423/424A) was pre-incubated with substrate 2 μl fructose-1,6-bisphosphate (FBP) (250 μM) in 2 ml dialysis buffer (20 mM Tris-HCl (pH 7.9), 20% (v/v) glycerol, 0.1 M KCl, 0.2 mM EDTA), followed by dialysis to remove the free FBP in 2 l dialysis buffer. PKM2-FBP complex or PKM2(C423/424A)-FBP complex was treated with 200-300 μM SNO-CoA for 10 min at room temperature, after which the activity of PKM2(WT) and PKM2(C423/424A) was measured. To measure PKM1 and PKLR activity, 10 ng PKM1-FBP complex, PKLR-FBP complex or PKM2-FBP complex was treated with 0, 50, 100, 200 or 300 μM SNO-CoA for 10 min at room temperature before assay. To measure PK activity in kidney, kidneys were mechanically homogenized in lysis buffer (50 mM phosphate buffer, pH 7.0, 150 mM NaCl, 0.1 mM EDTA, 0.1 mM DTPA, 1 mM PMSF, and protease inhibitor mixture (Roche)). Extracts were clarified by centrifugation (20,000g, 4 °C, 20 min, ×2), and protein concentration was determined by BCA assay. Then, 10 μl (0.1 μg/μl) lysate was used to measure PKM2 activity. Assay of PKM2 activity followed the protocol of the Pyruvate Kinase Activity Colorimetric/Fluorometric Assay Kit (Biovision). PKM2 dimer and tetramer formation. The assay of PKM2 dimer and tetramer in vitro was carried out as previously described 41 . In brief, after 40 ng PKM2-FBP complex was treated with 200-300 μM SNO-CoA for 10 min at room temperature, 5 μl fresh glutaraldehyde (50%) was added to a reaction mixture containing 100 mM HEPES (pH 7.5) for 5 min at 37 °C. The cross-linking reaction was terminated by addition of 5 μl 1M Tris-HCl (PH 8.0). Equal amounts of protein were separated using a 4-20% Criterion Precast Midi Protein Gel (BIO-RAD) and monomer, dimer and tetramer forms of PKM2 were detected with PKM2 antibody (sc-365684, Santa Cruz Biotechnology). Western blot analysis. Proteins were extracted from cells or tissues and subjected to 4-20% Criterion Precast Midi Protein Gel electrophoresis. Blotted membranes were incubated overnight at 4 °C with primary antibodies, and washed with PBS containing 0.1% Tween-20 before incubation with HRP-conjugated secondary antibody (anti-mouse or anti-rabbit IgG (Promega)) for 1 h followed by chemiluminescent detection (ECL (GE Healthcare)). Antibodies used for western blotting included: rabbit polyclonal anti-AKR1A1 (15054-1-AP, Proteintech Group), rabbit monoclonal anti-PKM1 (D30G6, Cell Signaling), rabbit monoclonal anti-PKM2 (D78A4, Cell Signaling), rabbit polyclonal anti-PKLR (AV41699, Sigma), rabbit polyclonal anti-NOS1 (sc-8309, Santa Cruz Biotechnology), rabbit polyclonal anti-NOS2 (sc-8310, Santa Cruz Biotechnology), rabbit polyclonal anti-NOS3 (sc-654, Santa Cruz Biotechnology), mouse anti-eNOS (pS1177) (612393, BD Transduction Laboratory), mouse monoclonal p97 (10R-P104A, Fitzgerald), rabbit monoclonal GAPDH (Ab181602, abcam), mouse monoclonal Myc (M047-3, MBL), mouse monoclonal Flag-M2 (F3165, Sigma), and mouse monoclonal V5 (R960-25, Invitrogen). Quantification of western blots was carried out with ImageJ (NIH). Expression of PKM1, PKM2 and PKLR. To measure the expression of PKM1, PKM2 and PKLR after AKI, kidney samples were taken from AKI-injured wildtype mice after 1, 3 or 7 days. To compare the expression of PKM1, PKM2 and PKLR between the kidneys of Akr1a1 +/+ and of Akr1a1 −/− mice, kidneys were removed after 24 h of AKI. Kidney samples were mechanically homogenized in lysis buffer (50 mM phosphate buffer, pH 7.0, 150 mM NaCl, 0.1 mM EDTA, 1 mM PMSF, and protease inhibitor mixture (Roche)). Extracts were clarified by centrifugation (20,000g, 4 °C, 20 min, ×2) , and protein concentration was determined by BCA assay. The expression of PKM1, PKM2 and PKLR was examined using western blot. GSSG/GSH and NADPH/NADP + . The GSSG/GSH ratio was assayed using the GSH/GSSG-Glo Assay kit from Promega. Mouse kidney samples (20 mg) were mechanically homogenized in 100 μl total glutathione lysis reagent for total glutathione measurement or 100 μl oxidized glutathione lysis reagent for GSSG measurement. Extracts were clarified by centrifugation (20,000g, 4 °C, 20 min, ×2) and 50 μl supernatant was transferred to the plate reader. Subsequently, 50 μl luciferin generation reagent was added to all wells, and assays were mixed and incubated for 30 min. Then, 100 μl luciferin detection reagent was added to wells followed by mixing. After 15 min of incubation, luminescence was measured using a luminometer. The NADPH/NADP + assay was carried out using the NADP/NADPH Assay kit from Abcam. Mouse kidney samples (50 mg) were mechanically homogenized in 500 μl of NADP/NADPH extraction buffer. Extracts were clarified by centrifugation (20,000g, 4 °C, 10 min) and proteins in the supernatant were removed using Amicon Ultra-0.5 ml Centrifugal Filters. The filtrate was used for assays following the manufacturer's protocol. Lipid peroxidation. Mouse kidney samples (25 mg) were mechanically homogenized in 250 μl of RIPA buffer (Invitrogen) containing protease inhibitors and 4 μl 2% (w/v) of the lipid antioxidant BHA. After centrifuging the extract at 160g for 10 min at 4 °C, the supernatant was used for analysis. For cells, 2 × 10 7 cells in 1 ml PBS were sonicated on ice for 10 s and the whole homogenate was used in assays. Next, 100 μl of homogenate or 100 μl standard (malondialdehyde) was combined with 10 μl of TCA-TBA-HCl reagent (0.5% (w/v) TBA in 20% (w/v) TCA and 0.33 N HCl) and mixed thoroughly. Then, 1.5 μl 2% (w/v) of the lipid antioxidant BHA was added to prevent lipid peroxidation during the assay. The solution was heated for 15 min in a boiling water bath. After cooling, the flocculent precipitate was removed by centrifugation at 1,000g for 10 min. Subseqently, 150 μl sample or standard (in duplicate) was loaded onto the plate reader. The absorbance of the supernatant was measured at 532 nm against a blank that contained reagents minus homogenate. Levels of TBARS (malondialdehyde (MDA) equivalent) were determined with an MDA standard curve. Metabolomics. Metabolic assays were carried out as described previously 42 . For metabolomic measurements, snap-frozen kidneys were cut to equal weights (20 mg per specimen) and mechanically homogenized into four volumes of ice-cold water. In brief, sugars, sugar phosphates, organic acids, bile acids, nucleotides and other anionic polar metabolites were measured in 30 μl of tissue homogenate using hydrophilic interaction liquid chromatography and multiple reaction monitoring in the negative ion mode on a 5500 QTRAP MS (SCIEX). Amino acids, amines, acylcarnitines, nucleotides, and other cationic polar metabolites were measured in 10 μl of tissue homogenate using hydrophilic interaction liquid chromatography coupled with nontargeted, positive ion mode MS analysis on an Exactive Plus Orbitrap MS (Thermo Scientific). Results were analysed in MetaboAnalyst (http:// www.metaboanalyst.ca). Statistics. Statistics were analysed using Minitab express and GraphPad Prism. Any outliers in data were identified and excluded using GraphPad Prism. Comparisons between continuous characteristics of subject groups were analysed with twotailed Student's t-test using GraphPad Prism. For comparisons among more than two groups, one-way ANOVA with Tukey's post hoc test in Minitab express was used. Survival was analysed by Kaplan-Meier estimation using GraphPad Prism. Overlap of S-nitrosylated proteins in three independent experiments (SNO-RACcoupled quantitative MS) and interactions between the nitrosoproteome and SCoR-AKR1A1 interactome were analysed using the SAS program. No statistical methods were used to predetermine sample size. Mice were randomized to experimental intervention versus control. Each mouse was assigned a code number to enable blinded sham or AKI surgery. Samples were assigned a code number to enable blinded quantitative analyses and measurements including: metabolomics, iTRAQ-coupled LC-MS/MS, SNO/FeNO (using photolysis/chemiluminescence), histology, mitochondrial morphology, serum creatinine and serum BUN. After all data were collected, the results were analysed and decoded. The investigators were not blinded during other experiments and outcome assessments. Bar graphs with the corresponding dot plots were created using GraphPad Prism. Results are presented as mean ± s.d. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data availability
The authors declare that the data supporting the findings of this study are available within the paper and its Supplementary Information. All datasets generated and/or analysed in the current study are available from the corresponding author upon reasonable request. Supplementary Fig. 1 contains scanned complete images of western blots. All experimental data from mice models are provided as Source Data. 
Letter reSeArCH
